#ASH25: Vertex, CRISPR say Casgevy shows promise in younger childrennews2025-11-03T14:00:17+00:00November 3rd, 2025|Endpoints News|
Kimberly-Clark inks $40B+ deal for Kenvuenews2025-11-03T13:52:55+00:00November 3rd, 2025|Endpoints News|
UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessingnews2025-11-03T13:34:28+00:00November 3rd, 2025|Endpoints News|
AstraZeneca, Lilly, Merck contribute $120M to support manufacturing talent in Virginianews2025-11-03T13:19:48+00:00November 3rd, 2025|Endpoints News|
Tempero halts substance use disorder drug, is ‘assessing strategic alternatives’news2025-11-03T12:01:54+00:00November 3rd, 2025|Endpoints News|
Caribou says it’s cracked ‘off-the-shelf’ cell therapy, but needs to raise money to move forwardnews2025-11-03T12:00:16+00:00November 3rd, 2025|Endpoints News|
Roche, Manifold Bio to advance new brain shuttles in pact worth up to $2B+news2025-11-03T11:45:30+00:00November 3rd, 2025|Endpoints News|
BioNTech ups sales guidance after Bristol Myers’ bispecific paymentnews2025-11-03T11:45:21+00:00November 3rd, 2025|Endpoints News|
Amgen Ventures joins $141M Series B for Italian gene therapy biotech AAVantgardenews2025-11-03T08:00:27+00:00November 3rd, 2025|Endpoints News|
Tidmarsh’s exit at FDA pushes an agency in transition further toward instabilitynews2025-11-03T02:48:10+00:00November 3rd, 2025|Endpoints News|
